Neoplasms Clinical Trials in Boston, Massachusetts

8 studies are recruiting for neoplasms in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o…

   Stage

   Phase 2

   Ages

   Any age

   Site

   Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   222 in total

   Run by

   Celgene

   See if you can join NCT03435796 on ClinicalTrials.gov

2. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

   This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was design…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   86 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT05386108 on ClinicalTrials.gov

3. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

   This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   19 in total

   Run by

   Marengo Therapeutics, Inc.

   See if you can join NCT05592626 on ClinicalTrials.gov

4. A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

   The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New stu…

   Stage

   Phase 2

   Ages

   1 to 39

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   72 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05999994 on ClinicalTrials.gov

5. A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

   The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Boston Medical Center, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07258836 on ClinicalTrials.gov

6. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

   The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Boston, Massachusetts

   Locations

   65 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06431594 on ClinicalTrials.gov

7. A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

   The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combinat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Boston, Massachusetts

   Locations

   67 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06551142 on ClinicalTrials.gov

8. Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

   The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston, Massachusetts

   Locations

   3 in total

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT04442724 on ClinicalTrials.gov